Amendments to the Claims

This listing of claims will replace all prior versions, and listing, of claims in the application.

Listing of Claims

1. (original): A compound of formula (I):



(I)

wherein

R^1 is C_1-C_6 alkyl (optionally substituted with 1, 2 or 3 halo substituents and/or with 1 substituent selected from -S-(C_1-C_3 alkyl), -O-(C_1-C_3 alkyl) (optionally substituted with 1, 2 or 3 F atoms), -O-(C_3-C_6 cycloalkyl), -SO_2-(C_1-C_3 alkyl), -CN, -COO-(C_1-C_2 alkyl) and –OH); C_2-C_6 alkenyl; $(CH_2)_q$-Ar_2; or a group of formula (i) or (ii)



(i)



(ii)

R^2, R^3 and R^4 are each independently selected from hydrogen or C_1-C_2 alkyl;

R^5, R^6, R^7 and R^8 are each independently selected from hydrogen or C_1-C_2 alkyl;

-X- is a bond, -CH_2-, -CH=CH-, -O-, -S-, or -SO_2-;

-Y- is a bond, -CH_2- or -O-;

-Z is hydrogen, –OH or -O-(C_1-C_3 alkyl);

p is 0, 1 or 2;

q is 0, 1 or 2;

r is 0 or 1;

s is 0, 1, 2 or 3;

t is 0, 1, 2, 3 or 4;

Ar_1 is selected from:

(i) a phenyl group or a 5- or 6-membered monocyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents), benzyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within a 5- or 6-membered monocyclic heteroaromatic group; or

(ii) a naphthyl group or an 8-, 9- or 10-membered bicyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within an 8-, 9- or 10-membered bicyclic heteroaromatic group; and

Ar_2 is selected from

(i) a phenyl group or a 5- or 6-membered monocyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4 or 5 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within a 5- or 6-membered monocyclic heteroaromatic group; or

(ii) a naphthyl group or an 8-, 9- or 10-membered bicyclic heteroaromatic group each of which is optionally substituted with 1, 2, 3, 4, 5 or 6 substituents (depending on the number of available substitution positions) each independently selected from halo, cyano, C_1-C_4alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) with the proviso that only C_1-C_4alkyl may be a substituent for the H of any -NH- moiety present within an 8-, 9- or 10-membered bicyclic heteroaromatic group;

or a pharmaceutically acceptable salt thereof; provided that:

(a) the cyclic portion of the group of formula (i) must contain at least three carbon atoms and not more than seven ring atoms;

(b) when –X- is –CH=CH-, then the cyclic portion of the group of formula (i) must contain at least five carbon atoms;

(c) when –Z is –OH or -O-(C_1-C_3 alkyl), then –X- is -CH_2-;

(d) when –Y- is –O- then p cannot be 0; and

(e) the compound 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile is excluded.

2. (currently amended): A compound according to claim 1, wherein

Ar_1 is phenyl, pyridinyl, thiazolyl, benzothiophenyl or naphthyl; wherein said phenyl, pyridinyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said benzothiophenyl or naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, cyano, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms), -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms), and -S-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms); and

Ar_2 is naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, C_1-C_4 alkyl (optionally substituted with 1, 2 or 3 F atoms) and -O-(C_1-C_4 alkyl) (optionally substituted with 1, 2 or 3 F atoms).

3. (currently amended): A compound according to claim 1, ~~or claim 2~~ wherein R^1 is C_1-C_6 alkyl, C_2-C_6 alkenyl, -$(CH_2)_m$-CF_3, -$(CH_2)_n$-S-(C_1-C_3 alkyl), -CH_2-COO-(C_1-C_2 alkyl), -(C_1-C_5 alkylene)-O-(C_1-C_3 alkyl), -(C_1-C_5 alkylene)-O-(C_3-C_6 cycloalkyl), -(C_1-C_5 alkylene)-SO_2-(C_1-C_3 alkyl), -(C_1-C_5 alkylene)-OCF_3, -(C_1-C_6 alkylene)-OH, -(C_1-C_5 alkylene)-CN, -$(CH_2)_q$-Ar_2 or a group of formula (ia), (ib) or (ii)



(ia) (ib) (ii)

R^2, R^3, R^4, R^5, R^6, R^7, R^8, -X-, -Y-, p, q, r and s are as defined in claim 1;

m is 1, 2 or 3;

n is 1, 2 or 3;

t is 2, 3 or 4;

-Ar_1 is phenyl, pyridinyl, thiazolyl or naphthyl; wherein said phenyl, pyridinyl or thiazolyl group may be substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl, cyano, C_1-C_4 alkyl, -O-(C_1-C_4 alkyl), -O-(C_1-C_4 difluoroalkyl), -O-(C_1-C_4 trifluoroalkyl), -S-(C_1-C_4 alkyl), -S-(C_1-C_2 trifluoroalkyl) and/or with 1 substituent selected from pyridinyl, pyrazolyl, phenyl (optionally substituted with 1, 2 or 3 halo substituents) and phenoxy (optionally substituted with 1, 2 or 3 halo substituents); and wherein said naphthyl group may be optionally substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl, cyano, C_1-C_4 alkyl, -O-(C_1-C_4 alkyl), -O-(C_1-C_4 difluoroalkyl), -O-(C_1-C_4 trifluoroalkyl), -S-(C_1-C_4 alkyl), -S-(C_1-C_2 trifluoroalkyl);

Ar_2 is naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl, wherein said naphthyl, pyridinyl, thiazolyl, furanyl, thiophenyl, benzothiophenyl, or phenyl may be substituted with 1, 2 or 3 substituents each independently selected from halo, C_1-C_4 alkyl, trifluoromethyl and -O-(C_1-C_4 alkyl).

4. (currently amended): A compound ~~according to any one of claims 1 to 3~~ of claim 1, wherein R^2, R^3, R^4, R^5, R^6, R^7, and R^8 are each ~~is~~ hydrogen.

5. (canceled)

6. (canceled)

7. (canceled)

8. (currently amended): A compound ~~according to any one of claims 1 to 5~~ of claim 1, wherein R^1 is C_1-C_6 alkyl.

9. (canceled)

10. (currently amended): A compound ~~according to any one of claims 1 to 5~~ of claim 1, wherein R^1 is -(C_4-C_5 alkylene)-OH.

11. (currently amended): A compound ~~according to any one of claims 1 to 7~~ of claim 1, wherein R^1 is a group of formula (i), r is 0, s is 2, t is 2, –Z is hydrogen and -X- is -O-, –S- or $–SO_2$-.

12. (canceled)

13. (currently amended): A compound ~~according to any one of claims 1 to 7~~ of claim 1, wherein R^1 is a group of formula (i), r is 0, s is 1, 2 or 3, t is 1, –Z is hydrogen and -X- is –CH_2-.

14. (currently amended): A compound ~~according to any one of claims 1 to 7~~ of claim 1, wherein R^1 is a group of formula (i), r is 1, s is 0, 1, 2 or 3, t is 1, –Z is hydrogen and -X- is $-CH_2-$.

15. (canceled)

16. (currently amended): A compound ~~according to any one of claims 1 to 7~~ of claim 1, wherein R^1 is $-(CH_2)_q-Ar_2$, and q is 1.

17. (currently amended): A compound according to claim 16, wherein $-Ar_2$ is pyridinyl, phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl or C_1-C_4 alkyl.

18. (currently amended): A compound ~~according to any one of claims 1 to 17~~ of claim 1, wherein $-Ar_1$ is phenyl; phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1-C_4 alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl, phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents; pyridinyl; or pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1-C_4 alkyl and/or with 1 substituent selected from phenyl and phenyl substituted with 1, 2 or 3 halo substituents.

19. (currently amended): A compound ~~according to any one of claims 1 to 18~~ of claim 1, wherein $-Ar_1$ is phenyl or phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1-C_4 alkyl and/or with 1 substituent selected from phenyl, phenyl substituted with 1, 2 or 3 halo substituents, pyridinyl, pyrazolyl, phenoxy and phenoxy substituted with 1, 2 or 3 halo substituents.

20. (canceled)

21. (canceled)

22. (currently amended): A compound ~~according to any one of claims 1 to 18~~ of claim 1, wherein $-Ar_1$ is pyridinyl or pyridinyl substituted with 1, 2 or 3 substituents each independently selected from halo, trifluoromethyl and C_1-C_4 alkyl and/or with 1 substituent selected from phenyl and phenyl substituted with 1, 2 or 3 halo substituents.

23. (canceled)

24. (currently amended): A pharmaceutical composition, comprising a compound ~~as claimed in any one of claims 1 to 23~~ of claim 1 or a pharmaceutically acceptable salt thereof, or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier.

25. (canceled)

26. (canceled)

27. (currently amended): A method for inhibiting the uptake of one or more monoamines selected from serotonin, dopamine, and norepinephrine in a mammal, comprising administering to a mammal in need of such inhibition an effective amount of a compound ~~as claimed in any one of Claims 1 to 23~~ of claim 1 or a pharmaceutically acceptable salt thereof, or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof.

28. (currently amended): A method for treating disorders associated with dysfunction of the uptake of one or more monoamines selected from serotonin, dopamine, and norepinephrine in a mammal, comprising administering to a patient in need thereof an effective amount of a compound ~~as claimed in any one of claims 1 to 23~~ of claim 1 or a pharmaceutically acceptable salt thereof, or 3-[(phenylmethyl)-(3S)-3-pyrrolidinylamino]-propanenitrile or a pharmaceutically acceptable salt thereof.

29. (currently amended): A method for treating ~~a disorder selected from the group consisting of addictive disorder and withdrawal syndrome, an adjustment disorder (including depressed mood, anxiety, mixed anxiety and depressed mood, disturbance of conduct, and~~

~~mixed disturbance of conduct and mood), an age-associated learning and mental disorder (including Alzheimer's disease), alcohol addiction, anorexia nervosa, apathy, an attention-deficit disorder (ADD) due to general medical conditions,~~ attention-deficit hyperactivity disorder (ADHD), ~~including the predominantly inattentive type of ADHD and the predominantly hyperactive-impulsive type of ADHD, bipolar disorder, bulimia nervosa, chronic fatigue syndrome, chronic or acute stress, cognitive disorders (including mild cognitive impairment (MCI) and cognitive impairment associated with schizophrenia (CIAS)), communication disorders (including stuttering, expressive language disorder, mixed receptive-expressive language disorder, phonological disorder and communication disorder not otherwise specified), conduct disorder, cyclothymic disorder, dementia of the Alzheimers type (DAT), depression (including adolescent depression and minor depression), dysthymic disorder, emotional dysregulation (including emotional dysregulation associated with ADHD, borderline personality disorder, bipolar disorder, schizophrenia, schizoaffective disorder and intermittent explosive disorder), fibromyalgia and other somatoform disorders (including somatization disorder, conversion disorder, pain disorder, hypochondriasis, body dysmorphic disorder, undifferentiated somatoform disorder, and somatoform NOS), generalized anxiety disorder (GAD), hot flashes or vasomotor symptoms, hypotensive states including orthostatic hypotension, impulse control disorders (including intermittent explosive disorder, kleptomania, pyromania, pathological gambling, trichotillomania and impulse control disorder not otherwise specified), incontinence (i.e., stress incontinence, genuine stress incontinence, and mixed incontinence), an inhalation disorder, an intoxication disorder, learning disabilities (including developmental speech and language disorders (such as developmental articulation disorder, developmental expressive language disorder and developmental receptive language disorder), learning disorders (such as reading disorder, mathematics disorder, disorder of written expression and learning disorder not otherwise specified) and motor skills disorders (such as developmental coordination disorder)), mania, migraine headaches, nicotine addiction, obesity (i.e., reducing the weight of obese or overweight patients), obsessive compulsive disorders and related spectrum disorders, oppositional defiant disorder, pain including chronic pain, neuropathic pain and antinociceptive pain, panic disorder, peripheral neuropathy, post-traumatic stress disorder, personality change due to a general medical condition (including labile type, disinhibited type, aggressive type, apathetic type, paranoid type, combined type and unspecified type), pervasive developmental disorders (including autistic disorder, Asperger's disorder, Rett's disorder, childhood disintegrative disorder, and pervasive developmental~~

~~disorder not otherwise specified), premenstrual dysphoric disorder (i.e., premenstrual syndrome and late luteal phase dysphoric disorder), psoriasis, a psychoactive substance use disorder, a psychotic disorder (including schizophrenia, schizoaffective and schizophreniform disorders), seasonal affective disorder, selective serotonin reuptake inhibition (SSRI) "poop out" syndrome (i.e., wherein a patient who fails to maintain a satisfactory response to SSRI therapy after an initial period of satisfactory response), a sleep disorder (such as narcolepsy and enuresis), social phobia (including social anxiety disorder), a specific developmental disorder, TIC disorders (e.g., Tourette's Disease), tobacco addiction and vascular dementia,~~ comprising administering to a patient in need thereof an effective amount of a compound ~~as claimed in any one of claims 1 to 23~~ of claim 1 which selectively inhibits the reuptake of norepinephrine over serotonin and dopamine, or a pharmaceutically acceptable salt thereof.

30. (canceled)

31. (canceled)

32. (canceled)

33. (canceled)

34. (canceled)

35. (canceled)

36. (canceled)